Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS4 | Q9NRS4 | 5/20 | 0.55 |
| ▸ | P2RX1 | P51575 | 4/20 | 0.55 |
| ▸ | P2RX4 | Q99571 | 4/20 | 0.55 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | IKBKB | O14920 | 1/20 | 0.52 |
| ▸ | CHUK | O15111 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
| ▸ | FLT3 | P36888 | 1/20 | 0.52 |
| ▸ | MYLK | Q15746 | 1/20 | 0.52 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | XPO1 | O14980 | 1/20 | 0.45 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13698751 | 0.92 | TMPRSS4 (0.55) | TMPRSS4P2RX1P2RX4P2RX7MEN1 | |
| SCHEMBL6101665 | 0.85 | GAA (0.50) | TMPRSS4P2RX1P2RX4P2RX7HSD17B10 | |
| SCHEMBL3498004 | 0.84 | KMT2A (0.52) | P2RX1P2RX4P2RX7MEN1KMT2A | |
| SCHEMBL3496734 | 0.83 | TMPRSS4 (0.56) | TMPRSS4P2RX1P2RX4P2RX7MEN1 | |
| SCHEMBL6102602 | 0.82 | TMPRSS4 (0.50) | TMPRSS4P2RX1P2RX4P2RX7MEN1 | |
| SCHEMBL6102407 | 0.81 | RAB9A (0.50) | TMPRSS4P2RX1POLBRAB9ASMN1; SMN2 | |
| SCHEMBL3498301 | 0.80 | EPHX1 (0.49) | P2RX1P2RX4P2RX7KMT2AALDH1A1 | |
| SCHEMBL4498909 | 0.80 | POLB (0.53) | TMPRSS4KMT2AHSD17B10ALDH1A1POLB | |
| SCHEMBL6101008 | 0.79 | POLB (0.54) | TMPRSS4P2RX1P2RX4P2RX7MEN1 | |
| SCHEMBL19612142 | 0.78 | TP53 (0.48) | TMPRSS4KMT2AHSD17B10ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1512397-B1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | INST MED MOLECULAR DESIGN INC (JP) | 2014-10-08 | — | — | EP | disclosed |
| US-20100113770-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-05-06 | — | — | US | disclosed |
| US-7626042-B2 | O-substituted hydroxyaryl derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-12-01 | — | — | US | disclosed |
| US-20060094718-A1 | 2-Morpholinocarbonyloxy-),5-(phenylethenyl,N-((3,5-bistrifluoromethyl-)phenyl)-benzamide; inhibitors of nuclear factor kappa B activation; cytokine suppressive antiinflammatory drugs(interleukin (IL-1, IL-6, IL-8) inhibitors); tumor necrosis factor (TNF-alpha) inhibitors; side effects reduction | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094718-A1 | 2-Morpholinocarbonyloxy-),5-(phenylethenyl,N-((3,5-bistrifluoromethyl-)phenyl)-benzamide; inhibitors of nuclear factor kappa B activation; cytokine suppressive antiinflammatory drugs(interleukin (IL-1, IL-6, IL-8) inhibitors); tumor necrosis factor (TNF-alpha) inhibitors; side effects reduction | IL1A, TNF, NFKBIA | TMPRSS4 4278/4885P2RX1 2507/4885P2RX4 3900/4885 |
| US-20100113770-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | RELA, NFKBIA, NFE2 | TMPRSS4 3984/4885P2RX1 3644/4885P2RX4 4206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.